Clinical Trials Browser

Leukemia, Plasma Cell × daratumumab × Clear all

NCT05054478 2021-09-23

PCL-2

Phase 2 Not yet recruiting

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Phase 1 Withdrawn

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell